OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa
Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
A longitudinal study with four parallel cohorts with each participant followed for 2 years: two cohorts in Busia (high malaria transmission site) and two cohorts in Kampala (low malaria transmission). Each site will have a cohort of children living with HIV (CLHIV) and HIV- uninfected children and will be age-matched, enrolled in parallel, and followed for two years. All children will be enrolled without malaria infection, as determined by a negative blood smear at baseline.
Phase:
PHASE4
Details
Lead Sponsor:
Yale University
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
amodiaquine, artesunate drug combination Artemether, Lumefantrine Drug Combination